USPTO serial 88225549
PEBBLE LABS
Reviewed by CopyMark Law Group
Reg. 5819332Status 710
- Filing date
- Status date
- Registration date
- Jul 30, 2019
- Examiner
- ALESKOW, DAVID HOWARD
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PEBBLE LABS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Los Alamos, NM, CA
SANTA FE, NM, US
Los Alamos, NM, CA
LOS ALAMOS, NM, US
Los Alamos, NM, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David S. Kerr
DAVID S. KERR BERG HILL GREENLEAF RUSCITTI LLP1712 PEARL ST.BOULDER, CO 80302UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development of genetically engineered organisms, namely, genetically engineered algae that produce that produce waxes; Research and development of pharmaceuticals, therapeutics, and biologics; Research and development of new biological products for therapeutic use | SECTION 8 - CANCELLED | Jan 7, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Pebble Labs Inc.
- Other trademarks owned by PEBBLE LABS INC.
- Other trademarks owned by Pebble Labs Inc.
- Other trademarks owned by PEBBLE LABS, INC.
- Other trademarks owned by Pebble Labs Inc.
- Other trademarks in Class 042
- Similar marks named PEBBLE LABS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 13, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 30, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 6, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 9, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 30, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 14, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 10, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 5, 2019 | ALIE | ASSIGNED TO LIE | — |
| Mar 14, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 14, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 14, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 14, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 14, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 8, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 3, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 14, 2018 | NWAP | NEW APPLICATION ENTERED | — |